Key Highlights

  • Zenas BioPharma shares are trading at $28.73 in Thursday's session, up 6.53%.
  • The rebound follows the company's IgG4-related disease investor event and reiterated Buy ratings from brokerages with targets of $44 to $55.
  • Obexelimab offers at-home weekly subcutaneous dosing, compared with the intravenous infusion used by an existing therapy.
  • The FDA decision date for obexelimab in IgG4-related disease is May 27, 2027.

Investor Event Sparks a Rebound After a Weak Week

Zenas BioPharma (NASDAQ:ZBIO) is rebounding in Thursday's session, trading near $28.73 and recovering part of a roughly 9.7% decline over the past week. The Waltham, Massachusetts-based clinical-stage company develops immunology therapies for autoimmune disease, led by obexelimab, a bifunctional antibody targeting CD19 and FcγRIIb, and orelabrutinib, an oral BTK inhibitor in development for progressive multiple sclerosis.

Volume is running below average and the broader healthcare sector is flat to slightly lower, so the gain looks specific to the company.

At-Home Weekly Dosing Is the Pitch Against an Infusion

Brokerages that reiterated Buy ratings, with targets from $44 to $55, pointed to obexelimab's at-home weekly subcutaneous dosing as a differentiator. The comparison is with the intravenous infusion required for Uplizna, the existing therapy from Amgen (NASDAQ:AMGN) in IgG4-related disease.

A Market Sized at About $4 Billion and a May 2027 Decision Date

Zenas sizes the U.S. IgG4-related disease market at about $4 billion. The FDA has accepted the Biologics license application for obexelimab, with a decision date of May 27, 2027, and a European Medicines Agency submission is anticipated in the second half of 2026.

The company is still pre-revenue from product sales and funds operations through capital markets.

Phase 2 SunStone Lupus Data Is the Next Test

The next near-term catalyst is Phase 2 SunStone data in systemic lupus erythematosus, expected in the fourth quarter of 2026. Shares trade within a 52-week range of $13.50 to $44.60.